Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Positive Primary Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00674414
What this trial is testing

Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery

Who this might be right for
Breast Cancer
UNICANCER 82
Large-scale testing (Phase 3)Ended earlyNCT03050398
What this trial is testing

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 8
Testing effectiveness (Phase 2)UnknownNCT00931450
What this trial is testing

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Institut Català d'Oncologia 70
Testing effectiveness (Phase 2)Study completedNCT01975142
What this trial is testing

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

Who this might be right for
Metastatic Breast Cancer, HER2 Negative Primary Tumor
Institut Curie 155
Testing effectiveness (Phase 2)Study completedNCT02488564
What this trial is testing

Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer

Who this might be right for
HER-2 Positive Breast Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 49
Large-scale testing (Phase 3)Study completedNCT00045032
What this trial is testing

Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 5,099
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Not applicableApproved For MarketingNCT04100694
What this trial is testing

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Who this might be right for
NRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more
Merus B.V.
Large-scale testing (Phase 3)Study completedNCT04109066
What this trial is testing

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 521
Large-scale testing (Phase 3)Looking for participantsNCT03561740
What this trial is testing

The Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients

Who this might be right for
Breast Cancer
Sun Yat-sen University 794
Testing effectiveness (Phase 2)Study completedNCT01432223
What this trial is testing

Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab

Who this might be right for
Breast CancerHER-2 Positive Breast CancerEffects of Chemotherapy
Osaka Medical College 46
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Not applicableNot Yet RecruitingNCT07198672
What this trial is testing

Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag

Who this might be right for
HER2-positive Breast Cancer
Zhenzhen Liu 45
Large-scale testing (Phase 3)Study completedNCT01966471
What this trial is testing

Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1,846
Testing effectiveness (Phase 2)Study completedNCT01688609
What this trial is testing

Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer

Who this might be right for
HER2-positive Breast CancerStage II Breast CancerStage IIIA Breast Cancer
National Cancer Institute (NCI) 18
Large-scale testing (Phase 3)Study completedNCT01772472
What this trial is testing

Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1,486
Large-scale testing (Phase 3)Study completedNCT01358877
What this trial is testing

Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 4,804
Not applicableLooking for participantsNCT04660435
What this trial is testing

To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer

Who this might be right for
Metastatic Breast CancerER Positive Breast CancerHER2-negative Breast Cancer
Fondazione Sandro Pitigliani 150
Testing effectiveness (Phase 2)Study completedNCT00841828
What this trial is testing

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 102
Testing effectiveness (Phase 2)Active Not RecruitingNCT04802876
What this trial is testing

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

Who this might be right for
MSI-H Colorectal CancerMelanomaAnal Carcinoma+28 more
SOLTI Breast Cancer Research Group 184
Next Page